Identification of 11(13)-dehydroivaxillin as a potent therapeutic agent against non-Hodgkin's lymphoma

Despite great advancements in the treatment of non-Hodgkin lymphoma (NHL), sensitivity of different subtypes to therapy varies. Targeting the aberrant activation NF-κB signaling pathways in lymphoid malignancies is a promising strategy. Here, we report that 11(13)-dehydroivaxillin (DHI), a natural c...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Xinhua, Li, Huiliang, Jin, Huizi, Jin, Jin, Yu, Miao, Ma, Chunmin, Tong, Yin, Zhou, Li, Lei, Hu, Xu, Hanzhang, Zhang, Weidong, Liu, Wei, Wu, Yingli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5636986/
https://www.ncbi.nlm.nih.gov/pubmed/28906487
http://dx.doi.org/10.1038/cddis.2017.442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5636986/
https://www.ncbi.nlm.nih.gov/pubmed/28906487
http://dx.doi.org/10.1038/cddis.2017.442

Ejemplares similares